Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 27, Issue 3, 2009, Pages 491-494

  Jin, Tao ^a   Bokarewa, Maria ^a   Amu, Sylvie ^a   Tarkowski, Andrej ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; D dimer; Fibrinogen; Infliximab; Rituximab; Tissue type plasminogen activator

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLOSPORIN; D DIMER; FIBRINOGEN; INFLIXIMAB; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RITUXIMAB; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG INFUSION; FEMALE; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RISK REDUCTION; SHORT COURSE THERAPY; THROMBOSIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651152976     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17. (Pubitemid 41111466)
2. WOLFE F, MITCHELL DM, SIBLEY JT et al.: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-494
3. DEL RINCON ID, WILLIAMS K, STERN MP et al.: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-2745
4. GERLI R, SCHILLACI G, GIORDANO A et al.: CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004; 109: 2744-2748
5. GERLI R, SHERER Y, BOCCI EB et al.: Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann N Y Acad Sci 2007; 1108: 372-381
6. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ et al.: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis, Arthritis Rheum 2007; 57: 125-132
7. VAUDO G, MARCHESI S, GERLI R et al.: Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63: 31-35 (Pubitemid 38064600)
8. RIDKER PM, RIFAI N, ROSE L et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565
9. THOMPSON SG, KIENAST J, PYKE SD et al.: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-641
10. LOWE GD, YARNELL JW, SWEETNAM PM et al.: Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79: 129-133
11. MCENTEGART A, CAPELL HA, CRERAN D et al.: Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 640-644
12. INGEGNOLI F, FANTINI F, FAVALLI EG et al.: Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008; 31: 175-179
13. AGIRBASLI M, INANC N, BAYKAN OA et al.: The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin Exp Rheumatol 2006; 24: 580-583
14. GONZALEZ-GAY MA, DE MATIAS JM, GONZALEZ-JUANATEY C et al.: Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-86
15. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, DE MATIAS JM et al.: Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-379
16. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, GONZALEZ-JUANATEY C et al.: Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-316 (Pubitemid 351659139)
17. GONZALEZ-GAY MA, LLORCA J, GARCIA-UNZUETA MT et al.: High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol. 2008; 26: 596-603.
18. JACOBSSON LT, TURESSON C, GULFE A et al.: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1218
19. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A et al.: Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51: 447-450
20. GONZALEZ-JUANATEY C, LLORCA J, GARCIA-PORRUA C et al.: Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55: 150-153